JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45$54.65.At the core of this bullish outlook is Viking’s obesity drug candidate, oral-2735, which could be a significant player in the rapidly expanding GLP-1 market.Oral-2735 Could Be A Game ChangerJPMorgan highlights oral-2735's potential as a highly competitive treatment in the GLP-1 market, partic ...